Pharmaceuticals Eli Lily announced, this Wednesday (3/5), promising results from phase 3 of the clinical trial of the Alzheimer’s drug donamemab. According to the company, patients who took the drug had a 40% less decline in their ability to perform day-to-day tasks.
The drug also led to up to a 35% drop in the clinical progress of the disease. In addition, in half of the participants, no signs of Alzheimer’s progression were observed within 12 months of treatment.
More on the subject
-
Claudia Meireles
Study shows breathing exercises can fight Alzheimer’s
-
Health
Drug may silence Alzheimer’s-related genes, study finds
-
Health
Scientist predicts development of Alzheimer’s drug by 2040
-
Health
Alzheimer’s: exam that diagnoses in 20 minutes arrives in Brazil
“We are extremely happy that donanemab achieved such positive results and with statistics that give hope to people living with Alzheimer’s”, says doctor Daniel Skovronsky, one of those responsible for the study, in the pharmaceutical company’s statement.
Based on these results, the manufacturer will submit a request to the FDA, the body corresponding to Anvisa in the United States, to approve the use of the drug on a large scale.
promising results
The tests were carried out on 1,182 people who already live with dementia caused by Alzheimer’s. Participants were divided into two groups, depending on how long they lived with the disease, and the results were compared to patients who took a placebo.
“Our study showed that people at the beginning of living with the disease seem to respond better to treatment”, added the vice president of the neuroscience department at Eli Lily, Mark Mintun.
A 35% delay in disease progress from a clinical point of view was seen in patients with more recent diagnoses. Among those living longer with the disease, the reduction was 29%. Data were evaluated from magnetic resonance imaging and interviews with study participants.
In addition to slowing disease progression and allowing people with Alzheimer’s to maintain their independence longer, donamemab was associated with a 39% decrease in patients’ risk of progressing to the next stage of the disease.
window._taboola = window._taboola || (); _taboola.push({ mode: “thumbnails-c-3×1”, container: “taboola-mid-article”, placement: “Mid Article”, target_type: “mix” });
Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.
The post Alzheimer: medicine can delay the impacts of dementia by 40% first appeared on Metropolis.
